Health Condition 1: J849- Interstitial pulmonary disease, unspecified
Conditions
Interventions
Intervention1: TBLC (1.1mm): Trans Bronchial Lung Cryo-Biopsy using 1.1 mm Cryoprobe
Control Intervention1: TBLC(1.7 mm): Trans Bronchial Lung Cryo-Biopsy using 1.7 mm Cryoprobe
Sponsors
National Institute of TB and Respiratory Diseases
Eligibility
Inclusion criteria
Inclusion criteria: 1.Age more than 18 years. 2.Patients with forced vital capacity more than 50 percentage and diffusing capacity of lungs for carbon monoxide more than 35 percentage. 3.Patients willing to provide informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with Coagulopathy (thrombocytopenia less than 50000, prothrombin time international normalized ratio more than 1.5) 2.Patients with hemodynamic instability. 3.Patients with severe pulmonary hypertension (with estimated right ventricular systolic pressure more than 40 mm Hg or signs of right ventricular dysfunction on echocardiogram) 4.Patients with severe hypoxemia (PaO2 less than 55 mm Hg) on room air. 5.Patients with Diffuse Bullous Disease. 6.Patients unwilling to provide consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To compare the Diagnostic yield of Trans Bronchial Lung Cryo-Biopsy using 1.1 mm Vs 1.7 mm Cryoprobe in patients with Diffuse Parenchymal Lung Disease. 2.To compare the Safety of Trans Bronchial Lung Cryo-Biopsy using 1.1 mm Vs 1.7 mm Cryoprobe in patients with Diffuse Parenchymal Lung Disease. Timepoint: at baseline and 2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To Study the Clinico Radiological & Histopathological profile of these patients. 2. To monitor the procedural time & the patient s willingness to return for repeat procedure, if required. Timepoint: at baseline & 2 weeks | — |
Countries
India
Contacts
Public ContactDr Jitendra Kumar Saini
National Institute of TB and Respiratory Diseases
Outcome results
None listed